Key result
Metformin use prior to acute myocardial infarction in patients with type II diabetes was associated with significantly increased serum omentin-1 and decreased cardiac troponin-I levels (p < 0.001).
Why the study?
Does metformin therapy prior to acute myocardial infarction improve serum omentin-1 and cardiac troponin-I levels in patients with type II diabetes mellitus?
Population
115 subjects: 85 patients with type II diabetes mellitus and acute myocardial infarction, and 30 normal…
Comparison
Metformin therapy prior to the onset of acute… vs No metformin therapy prior to acute myocardial…
Design
Cross-sectional
Authors
Loading...
May not alter pre-MI metformin use in diabetes; hypothesis-generating for omentin-1 mediation, needs prospective confirmation.
Cross-Sectional (n=115)
Does metformin therapy prior to acute myocardial infarction improve serum omentin-1 and cardiac troponin-I levels in patients with type II diabetes mellitus?
p-value: p=< 0.001
Prior metformin use in diabetic patients presenting with acute MI is associated with higher levels of the cardioprotective biomarker omentin-1 and lower cardiac troponin-I levels.
Al‐kuraishy et al. (2015) conducted a cross-sectional in Type II diabetes mellitus and acute myocardial infarction (n=115). Metformin vs. No metformin prior to acute MI, and healthy controls was evaluated on Difference in biochemical parameters including serum omentin-1 and cardiac troponin-I levels (p=< 0.001). Metformin use prior to acute myocardial infarction in patients with type II diabetes was associated with significantly increased serum omentin-1 and decreased cardiac troponin-I levels (p < 0.001).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: